1. Reed, G.W., J.E. Rossi, and C.P. Cannon, Acute myocardial infarction. Lancet, 2017. 389(10065): p. 197-210.
2. Talman, V. and H. Ruskoaho, Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration. Cell Tissue Res, 2016. 365(3): p. 563-81.
3. McLaughlin, S., B. McNeill, J. Podrebarac, et al., Injectable human recombinant collagen matrices limit adverse remodeling and improve cardiac function after myocardial infarction. Nat Commun, 2019. 10(1): p. 4866.
4. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation, 1998. 97(22): p. 2202-12.
5. Dickstein, K., J. Kjekshus, and O.S.C.o.t.O.S. Group, Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet, 2002. 360(9335): p. 752-60.
6. McMurray, J.J., M. Packer, A.S. Desai, et al., Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med, 2014. 371(11): p. 993-1004.
7. Hellermann, J.P., S.J. Jacobsen, B.J. Gersh, et al., Heart failure after myocardial infarction: a review. Am J Med, 2002. 113(4): p. 324-30.
8. Issemann, I. and S. Green, Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature, 1990. 347(6294): p. 645-50.
9. Tenenbaum, A. and E.Z. Fisman, Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention? Cardiovasc Diabetol, 2012. 11: p. 140.
10. Wagner, N. and K.D. Wagner, The Role of PPARs in Disease. Cells, 2020. 9(11).
11. Penas, F.N., D. Carta, A.C. Cevey, et al., Pyridinecarboxylic Acid Derivative Stimulates Pro-Angiogenic Mediators by PI3K/AKT/mTOR and Inhibits Reactive Nitrogen and Oxygen Species and NF-kappaB Activation Through a PPARgamma-Dependent Pathway in T. cruzi-Infected Macrophages. Front Immunol, 2019. 10: p. 2955.
12. Berger, J. and D.E. Moller, The mechanisms of action of PPARs. Annu Rev Med, 2002. 53: p. 409-35.
13. Lin, J., A. Maimaitiyiming, S. Chen, M. Xiao, and Z. Xian, Hypoxia-induced miR-27 and miR-195 regulate ATP consumption, viability, and metabolism of rat cardiomyocytes by targeting PPARgamma and FASN expression. Aging (Albany NY), 2021. 13(7): p. 10158-10174.
14. Wei, W.Y., N. Zhang, L.L. Li, et al., Pioglitazone Alleviates Cardiac Fibrosis and Inhibits Endothelial to Mesenchymal Transition Induced by Pressure Overload. Cell Physiol Biochem, 2018. 45(1): p. 26-36.
15. Ni, G., K. Wang, Y. Zhou, et al., Citri reticulatae Pericarpium attenuates Ang II-induced pathological cardiac hypertrophy via upregulating peroxisome proliferator-activated receptors gamma. Ann Transl Med, 2020. 8(17): p. 1064.
16. Cheng, H., X. Wu, G. Ni, et al., Citri Reticulatae Pericarpium protects against isoproterenol-induced chronic heart failure via activation of PPARgamma. Ann Transl Med, 2020. 8(21): p. 1396.
17. Khandoudi, N., P. Delerive, I. Berrebi-Bertrand, et al., Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes, 2002. 51(5): p. 1507-14.
18. Shiomi, T., H. Tsutsui, S. Hayashidani, et al., Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation, 2002. 106(24): p. 3126-32.
19. Lu, Q., P. Guo, J. Guo, et al., Targeting peroxisome proliferator-activated receptors: A new strategy for the treatment of cardiac fibrosis. Pharmacol Ther, 2021. 219: p. 107702.
20. Li, X., J. Zhang, J. Huang, et al., A multicenter, randomized, double-blind, parallel-group, placebo-controlled study of the effects of qili qiangxin capsules in patients with chronic heart failure. J Am Coll Cardiol, 2013. 62(12): p. 1065-1072.
21. Zeng, S.L., S.Z. Li, C.J. Lai, et al., Evaluation of anti-lipase activity and bioactive flavonoids in the Citri Reticulatae Pericarpium from different harvest time. Phytomedicine, 2018. 43: p. 103-109.
22. Yu, X., S. Sun, Y. Guo, et al., Citri Reticulatae Pericarpium (Chenpi): Botany, ethnopharmacology, phytochemistry, and pharmacology of a frequently used traditional Chinese medicine. J Ethnopharmacol, 2018. 220: p. 265-282.
23. Duan, L., L. Guo, L.L. Dou, et al., Discrimination of Citrus reticulata Blanco and Citrus reticulata 'Chachi' by gas chromatograph-mass spectrometry based metabolomics approach. Food Chem, 2016. 212: p. 123-7.
24. Guo, J., H. Tao, Y. Cao, et al., Prevention of Obesity and Type 2 Diabetes with Aged Citrus Peel (Chenpi) Extract. J Agric Food Chem, 2016. 64(10): p. 2053-61.
25. Bhargava, P., V.K. Verma, S. Malik, et al., Hesperidin regresses cardiac hypertrophy by virtue of PPAR-gamma agonistic, anti-inflammatory, antiapoptotic, and antioxidant properties. J Biochem Mol Toxicol, 2019. 33(5): p. e22283.
26. Byun, E.B., H.M. Kim, H.Y. Song, and W.S. Kim, Hesperidin structurally modified by gamma irradiation induces apoptosis in murine melanoma B16BL6 cells and inhibits both subcutaneous tumor growth and metastasis in C57BL/6 mice. Food Chem Toxicol, 2019. 127: p. 19-30.
27. Wu, J., X. Ye, S. Yang, et al., Systems Pharmacology Study of the Anti-Liver Injury Mechanism of Citri Reticulatae Pericarpium. Front Pharmacol, 2021. 12: p. 618846.
28. Schobesberger, S., P. Wright, S. Tokar, et al., T-tubule remodelling disturbs localized beta2-adrenergic signalling in rat ventricular myocytes during the progression of heart failure. Cardiovasc Res, 2017. 113(7): p. 770-782.
29. Bhat, S., A. Chin, A. Shirakabe, et al., Recruitment of RNA Polymerase II to Metabolic Gene Promoters Is Inhibited in the Failing Heart Possibly Through PGC-1alpha (Peroxisome Proliferator-Activated Receptor-gamma Coactivator-1alpha) Dysregulation. Circ Heart Fail, 2019. 12(3): p. e005529.
30. Duan, S.Z., C.Y. Ivashchenko, M.G. Usher, and R.M. Mortensen, PPAR-gamma in the Cardiovascular System. PPAR Res, 2008. 2008: p. 745804.
31. Madrazo, J.A. and D.P. Kelly, The PPAR trio: regulators of myocardial energy metabolism in health and disease. J Mol Cell Cardiol, 2008. 44(6): p. 968-75.
32. Curley, D., B. Lavin Plaza, A.M. Shah, and R.M. Botnar, Molecular imaging of cardiac remodelling after myocardial infarction. Basic Res Cardiol, 2018. 113(2): p. 10.
33. Ziaeian, B. and G.C. Fonarow, Epidemiology and aetiology of heart failure. Nat Rev Cardiol, 2016. 13(6): p. 368-78.
34. Zeng, W., K.E. Huang, Y. Luo, et al., Nontargeted urine metabolomics analysis of the protective and therapeutic effects of Citri Reticulatae Chachiensis Pericarpium on high-fat feed-induced hyperlipidemia in rats. Biomed Chromatogr, 2020. 34(4): p. e4795.
35. Shu, Z., Y. Zhou, K. Chang, et al., Clinical features and the traditional Chinese medicine therapeutic characteristics of 293 COVID-19 inpatient cases. Front Med, 2020. 14(6): p. 760-775.
36. Ou, L.J., X.P. Sun, Q.D. Liu, S.Q. Mi, and N.S. Wang, [Effects of Rhizoma zingiberis and Pericarpium citri reticulatae extracts on myocardial ischemia in rats]. Zhong Yao Cai, 2009. 32(11): p. 1723-6.
37. Levantesi, G., A. Macchia, R. Marfisi, et al., Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol, 2005. 46(2): p. 277-83.
38. Zhou, B. and R. Tian, Mitochondrial dysfunction in pathophysiology of heart failure. J Clin Invest, 2018. 128(9): p. 3716-3726.
39. Di, W., J. Lv, S. Jiang, et al., PGC-1: The Energetic Regulator in Cardiac Metabolism. Curr Issues Mol Biol, 2018. 28: p. 29-46.
40. Duan, S.Z., C.Y. Ivashchenko, M.W. Russell, D.S. Milstone, and R.M. Mortensen, Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ Res, 2005. 97(4): p. 372-9.
41. Ma, Z.G., Y.P. Yuan, X. Zhang, et al., Piperine Attenuates Pathological Cardiac Fibrosis Via PPAR-gamma/AKT Pathways. EBioMedicine, 2017. 18: p. 179-187.
42. Peng, S., J. Xu, W. Ruan, S. Li, and F. Xiao, PPAR-gamma Activation Prevents Septic Cardiac Dysfunction via Inhibition of Apoptosis and Necroptosis. Oxid Med Cell Longev, 2017. 2017: p. 8326749.
43. Horita, S., M. Nakamura, N. Satoh, M. Suzuki, and G. Seki, Thiazolidinediones and Edema: Recent Advances in the Pathogenesis of Thiazolidinediones-Induced Renal Sodium Retention. PPAR Res, 2015. 2015: p. 646423.